Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy

Immune checkpoint inhibitors (ICI) have revolutionised cancer therapy. However, they have been effective in only a small subset of patients and a principal mechanism underlying immune-refractoriness is a ‘cold’ tumour microenvironment, that is, lack of a T-cell-rich, spontaneously inflamed phenotype...

Descripción completa

Detalles Bibliográficos
Autores principales: Motedayen Aval, Leila, Pease, James E., Sharma, Rohini, Pinato, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602874/
https://www.ncbi.nlm.nih.gov/pubmed/33081170
http://dx.doi.org/10.3390/jcm9103323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602874/
https://www.ncbi.nlm.nih.gov/pubmed/33081170
http://dx.doi.org/10.3390/jcm9103323

Ejemplares similares